Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Chromodomain-helicase-DNA-binding protein 2 (CHD2) mRNA is the transcript of the CHD2 gene, which encodes a member of the SNF2-like family of ATP-dependent chromatin remodeling proteins [1][2]. The CHD2 protein plays a critical role in regulating gene expression by modifying chromatin structure, a process essential for normal embryonic development and neuronal differentiation [1][3]. Mutations in the CHD2 gene, typically resulting in haploinsufficiency, are a primary cause of CHD2-related neurodevelopmental disorders, which are characterized by early-onset epilepsy, intellectual disability, and autism spectrum disorders [3]. Because these conditions arise from insufficient protein levels, the CHD2 mRNA has become a focal point for RNA-targeted therapeutic interventions [4]. Experimental strategies, such as the use of antisense oligonucleotides (ASOs), aim to modulate the splicing or stability of CHD2 mRNA to increase the production of functional CHD2 protein [4]. These approaches, including technologies like Targeted Augmentation of Nuclear Gene Output (TANGO), seek to restore normal chromatin remodeling activity and alleviate the severe neurological symptoms associated with CHD2 deficiency [4]. [1] UniProt Consortium. "CHD2 - Chromodomain-helicase-DNA-binding protein 2 - Homo sapiens (Human)." UniProtKB, O14647. [2] National Center for Biotechnology Information (NCBI). "CHD2 chromodomain helicase DNA binding protein 2 [Homo sapiens (human)]." Gene ID: 1106. [3] Suls, A., et al. (2013). "De novo loss-of-function mutations in CHD2 cause a fever-sensitive myoclonic epileptic encephalopathy." Nature Genetics, 45(5), 557-561. [4] Stoke Therapeutics. "Pipeline: CHD2-related neurodevelopmental disorders." stoketherapeutics.com.
Upregulation of protein expression via antisense oligonucleotide-mediated modulation of pre-mRNA splicing to increase productive mRNA levels and restore functional protein concentrations.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Chromodomain-helicase-DNA-binding protein 2 mRNA (CHD2 mRNA).